Citizens JMP analyst Daniel Stauder reiterated a Buy rating on Artivion (AORT – Research Report) today and set a price target of $33.00. The company’s shares closed yesterday at $23.77.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Stauder covers the Healthcare sector, focusing on stocks such as Atricure, Artivion, and Lemaitre Vascular. According to TipRanks, Stauder has an average return of 45.9% and a 44.44% success rate on recommended stocks.
Artivion has an analyst consensus of Strong Buy, with a price target consensus of $32.50, representing a 36.73% upside. In a report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $35.00 price target.
The company has a one-year high of $32.33 and a one-year low of $21.97. Currently, Artivion has an average volume of 473.7K.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year. Most recently, in March 2025, Lance Berry, the EVP & CFO of AORT sold 4,909.00 shares for a total of $121,743.20.
Read More on AORT: